Autologous cultured chondrocytes - Vericel

Drug Profile

Autologous cultured chondrocytes - Vericel

Alternative Names: Articel; Autologous cultured chondrocytes on porcine collagen membrane; MACI; MACI Implant; Matrix-applied-characterised-autologous-cultured-chondrocytes-Vericel; Matrix-induced autologous chondrocyte implant

Latest Information Update: 23 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Verigen AG
  • Developer Vericel Corporation
  • Class Cell therapies
  • Mechanism of Action Cartilage replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Knee injuries
  • Phase II Osteonecrosis

Most Recent Events

  • 17 Jul 2018 Phase-III clinical trials in Knee injuries (In adolescents, In children) in USA (Parenteral) (NCT03588975)
  • 23 Mar 2018 Interim efficacy and adverse events data from a SUMMIT extension trial in Knee injuries released by Vericel
  • 10 May 2017 Autologous cultured chondrocytes - Vericel licensed to Innovative Cellular Therapeutics in China, South Korea, Singapore, and other South-East Asia countries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top